CN103379915A - Hsa相关组合物及使用方法 - Google Patents

Hsa相关组合物及使用方法 Download PDF

Info

Publication number
CN103379915A
CN103379915A CN2011800674634A CN201180067463A CN103379915A CN 103379915 A CN103379915 A CN 103379915A CN 2011800674634 A CN2011800674634 A CN 2011800674634A CN 201180067463 A CN201180067463 A CN 201180067463A CN 103379915 A CN103379915 A CN 103379915A
Authority
CN
China
Prior art keywords
residue
hsa
domain iii
polypeptide
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800674634A
Other languages
English (en)
Chinese (zh)
Inventor
C·高
C·乔杜里
X·姚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
MedImmune Vaccines Inc
Original Assignee
MedImmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/024855 external-priority patent/WO2011103076A1/en
Application filed by MedImmune Vaccines Inc filed Critical MedImmune Vaccines Inc
Publication of CN103379915A publication Critical patent/CN103379915A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011800674634A 2011-02-15 2011-08-09 Hsa相关组合物及使用方法 Pending CN103379915A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2011/024855 2011-02-15
PCT/US2011/024855 WO2011103076A1 (en) 2010-02-16 2011-02-15 Hsa-related compositions and methods of use
PCT/US2011/047040 WO2012112188A1 (en) 2011-02-15 2011-08-09 Hsa-related compositions and methods of use

Publications (1)

Publication Number Publication Date
CN103379915A true CN103379915A (zh) 2013-10-30

Family

ID=46675795

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800674634A Pending CN103379915A (zh) 2011-02-15 2011-08-09 Hsa相关组合物及使用方法

Country Status (7)

Country Link
EP (1) EP2675471A4 (enExample)
JP (1) JP2014510518A (enExample)
KR (1) KR20140012094A (enExample)
CN (1) CN103379915A (enExample)
AU (1) AU2011359378A1 (enExample)
CA (1) CA2826683A1 (enExample)
WO (1) WO2012112188A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209482A (zh) * 2013-03-15 2015-12-30 阿菲博迪公司 新的多肽
CN108290941A (zh) * 2015-09-23 2018-07-17 百时美施贵宝公司 快解离速率的血清白蛋白结合性纤连蛋白iii型结构域

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
MX2012004793A (es) 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Variantes de albumina.
AU2011218294A1 (en) 2010-02-16 2012-08-30 Medimmune, Llc HSA-related compositions and methods of use
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
CA2838246C (en) 2011-06-13 2018-07-10 Csl Limited Antibodies against g-csfr and uses thereof
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
KR20150082422A (ko) * 2012-11-08 2015-07-15 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
CN105007722A (zh) 2013-02-16 2015-10-28 诺维信生物制药丹麦公司 药代动力学动物模型
EP3007717B1 (en) 2013-06-12 2018-08-29 Pharis Biotec GmbH Peptides with antagonistic activities against natural cxcr4
EP3044232A1 (en) * 2013-09-13 2016-07-20 Novozymes Biopharma DK A/S Albumin variants
CN105992770B (zh) * 2013-11-01 2021-06-25 奥斯陆大学 白蛋白的变体及其用途
CA2977675A1 (en) 2015-03-12 2016-09-15 Medimmune, Llc Method of purifying albumin-fusion proteins
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
CA3005953A1 (en) 2015-12-22 2017-06-29 Albumedix Ltd Improved protein expression strains
JP7146637B2 (ja) 2015-12-22 2022-10-04 アルブミディクス リミティド 改善されたタンパク質発現株
JP2020500306A (ja) 2016-11-04 2020-01-09 オーフス ウニベルシテット 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療
US11130979B2 (en) 2017-06-20 2021-09-28 Albumedix Ltd Protein expression strains
PL3717011T3 (pl) 2017-11-29 2023-03-27 Csl Limited Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
PT3793586T (pt) 2018-05-16 2024-07-10 Csl Ltd Variantes do receptor solúvel do complemento de tipo 1 e sua utilização
EA202191179A1 (ru) 2018-10-29 2021-09-09 Байоджен Ма Инк. Гуманизированные и стабилизированные варианты fc5 для улучшения транспорта через гематоэнцефалический барьер
AU2020343512A1 (en) 2019-09-06 2022-04-07 Novartis Ag Therapeutic fusion proteins
WO2021111143A1 (en) 2019-12-04 2021-06-10 Albumedix Limited Methods and compositions produced thereby
CN114478800B (zh) * 2021-02-05 2022-10-11 华南理工大学 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
WO2024089258A1 (en) 2022-10-28 2024-05-02 Aarhus Universitet Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
WO2025158071A1 (en) 2024-01-26 2025-07-31 Sartorius Albumedix Limited Retroviral preparations containing albumin for enhancing transduction efficiency, uses thereof for cell transduction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126920A2 (en) * 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US20110002888A1 (en) * 2001-12-21 2011-01-06 Human Gemone Sciences, Inc. Albumin Fusion Proteins
CN102781960B (zh) * 2010-02-16 2014-12-10 米迪缪尼有限公司 Hsa相关组合物及使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404270D0 (en) * 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
WO2010118169A2 (en) * 2009-04-08 2010-10-14 The Regents Of The University Of California Human protein scaffold with controlled serum pharmacokinetics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110002888A1 (en) * 2001-12-21 2011-01-06 Human Gemone Sciences, Inc. Albumin Fusion Proteins
WO2009126920A2 (en) * 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CN102781960B (zh) * 2010-02-16 2014-12-10 米迪缪尼有限公司 Hsa相关组合物及使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAN TERJE ANDERSEN ET AL.: "Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》, 12 January 2010 (2010-01-12), pages 4826 - 4836 *
VANIA E.KENANOVA ET AL.: "Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins", 《PROTEIN ENGINEERING, DESIGN & SELECTION》, 28 August 2010 (2010-08-28), pages 789 - 798 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209482A (zh) * 2013-03-15 2015-12-30 阿菲博迪公司 新的多肽
CN105209482B (zh) * 2013-03-15 2022-04-29 阿菲博迪公司 新的多肽
CN108290941A (zh) * 2015-09-23 2018-07-17 百时美施贵宝公司 快解离速率的血清白蛋白结合性纤连蛋白iii型结构域

Also Published As

Publication number Publication date
CA2826683A1 (en) 2012-08-23
JP2014510518A (ja) 2014-05-01
WO2012112188A1 (en) 2012-08-23
EP2675471A4 (en) 2015-01-28
KR20140012094A (ko) 2014-01-29
AU2011359378A1 (en) 2013-10-03
EP2675471A1 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
CN103379915A (zh) Hsa相关组合物及使用方法
CN102781960B (zh) Hsa相关组合物及使用方法
US9045564B2 (en) HSA-related compositions and methods of use
US10610568B2 (en) Compositions and methods of use for treating metabolic disorders
JP6166041B2 (ja) ミオチューブラリン１（ｍｔｍ１）ポリペプチドを含むキメラポリペプチドを使用して筋細管ミオパシーを処置するための方法および組成物
CN105189542A (zh) 用于治疗庞贝氏症的方法和组合物
US10781433B2 (en) Methods and compositions for treatment of Lafora disease
AU2019236270A1 (en) Methods and compositions for treatment of polyglucosan disorders
CN106957365B (zh) 一种单克隆抗体FnAb8及其应用
CN112930397A (zh) Enpp1多肽及其使用方法
JP2024178422A (ja) Ｅｎｐｐ１ポリペプチドおよびその使用方法
CN104926946B (zh) 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用
CN106957364B (zh) 一种单克隆抗体FnAb12及其应用
EP4630050A1 (en) Broadly neutralizing antibody-templated divalent immunogen vaccines
KR20250156726A (ko) Covid-19 융합 단백질에 대한 뉴클레오캡시드 항원 면역 요법 및 사용 방법
Lee Rational Engineering of Erythropoietin for Smarter Protein Therapeutics: Structure–Function Relationships and Molecular Geometry
HK40063598A (en) Enpp1 polypeptides and methods of using same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131030